DBV Technologies S.A. (DBVT): who owns it and who trades it
As of Nov 16, 2026, DBVT insiders reported 7 open-market sales worth $15.5M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bpifrance EPIC (Other), with $15.5M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling DBV Technologies
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DBVT
77 funds and institutions reported DBVT shares worth $344M at the end of Q2 2026, about 7% of the company. The largest holder is Mpm Bioimpact LLC with 1.2%.
Funds and institutions (13F) 7%Everyone else 93%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Mpm Bioimpact LLC | 3.67M | 1.24% | $60.1M | -30% |
| Siren, L.L.C. | 1.86M | 0.63% | $30.5M | No change |
| Vivo Capital, LLC | 1.84M | 0.62% | $30.3M | -31% |
| Perceptive Advisors LLC | 1.65M | 0.56% | $27.1M | +71% |
| Baker Bros. Advisors LP | 1.46M | 0.49% | $24M | No change |
| Artisan Partners Limited Partnership | 1.37M | 0.46% | $22.5M | -38% |
| UBS Group AG | 1.31M | 0.44% | $21.5M | +1551% |
| Morgan Stanley | 954,908 | 0.32% | $15.7M | +554% |
| Logos Global Management LP | 915,000 | 0.31% | $15M | New |
| Patient Square Capital LP | 909,474 | 0.31% | $14.9M | +31% |
| Octagon Capital Advisors LP | 574,200 | 0.19% | $9.4M | No change |
| ADAR1 Capital Management, LLC | 528,295 | 0.18% | $8.7M | -48% |
| Redmile Group, LLC | 410,440 | 0.14% | $6.7M | -16% |
| Duquesne Family Office LLC | 383,363 | 0.13% | $6.3M | No change |
| Ameriprise Financial Inc | 378,497 | 0.13% | $6.2M | +64% |
| Millennium Management LLC | 267,783 | 0.09% | $4.4M | -16% |
| Elmind Capital, LP | 265,000 | 0.09% | $4.3M | No change |
| Jane Street Group, LLC | 223,915 | 0.08% | $3.7M | +1884% |
| Ishara Investments LP | 184,500 | 0.06% | $3M | +80% |
| Yiheng Capital Management, L.P. | 170,142 | 0.06% | $2.8M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DBVT insiders reported $0 of open-market purchases and $15.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Pharis Mohideen | Chief Medical Officer | Sale | 464 | $2.70 | $1.3K | Form 4 |
| Jan 29, 2026 | Pharis Mohideen | Chief Medical Officer | Sale | 534 | $4.86 | $2.6K | Form 4 |
| Dec 18, 2025 | Bpifrance EPIC +4 | Other | Sale | 1.29M | $4.19 | $5.4M | Form 4 |
| Dec 17, 2025 | Bpifrance EPIC +4 | Other | Sale | 40,000 | $5.28 | $211K | Form 4 |
| Dec 17, 2025 | Bpifrance EPIC +4 | Other | Sale | 2.04M | $4.84 | $9.9M | Form 4 |
| Nov 21, 2025 | Pharis Mohideen | Chief Medical Officer | Sale | 1,624 | $2.77 | $4.5K | Form 4 |
| Nov 20, 2025 | Pharis Mohideen | Chief Medical Officer | Sale | 6,496 | $2.88 | $18.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bpifrance EPIC | Other | – | $15.5M | Dec 18, 2025 |
| Pharis Mohideen | Chief Medical Officer | – | $27.1K | Jul 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DBVT short interest
Low short interest. 0.3% of DBVT shares are sold short: about 1 share in 390. Over the last 12 reports the number of shares short went down 78%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 806,674 DBVT shares were sold short, 0.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 483,590 shares, buying them all back would take about 1.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 806,674 | 0.26% | -7% | 483,590 | 1.7 |
| Oct 15, 2026 | 872,075 | – | -22% | 438,225 | 2.0 |
| Sep 30, 2026 | 1.12M | – | -17% | 285,034 | 3.9 |
| Sep 15, 2026 | 1.35M | – | -15% | 410,543 | 3.3 |
| Aug 31, 2026 | 1.58M | – | -3% | 163,289 | 9.7 |
| Aug 14, 2026 | 1.63M | – | -12% | 411,320 | 4.0 |
| Jul 31, 2026 | 1.85M | – | +26% | 370,293 | 5.0 |
| Jul 15, 2026 | 2.94M | 0.50% | +13% | 187,661 | 7.8 |
| Jun 30, 2026 | 2.60M | 0.44% | -9% | 352,048 | 3.7 |
| Jun 15, 2026 | 2.85M | 0.48% | -15% | 259,294 | 5.5 |
| May 29, 2026 | 3.33M | 0.56% | -7% | 282,436 | 5.9 |
| May 15, 2026 | 3.60M | 0.61% | -1% | 179,255 | 10.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
DBV Technologies company events
DBV Technologies filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 28, 2026.
- Oct 28, 2026ResultsReleased financial results. Filing
- Sep 30, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing
- Jul 16, 2026ResultsReleased financial results. Filing
- Jun 29, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 Through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing.” A copy of the press release is attached as… Filing
- Jun 5, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- May 5, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Filing
- Jan 20, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March Financing.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form… Filing
- Dec 16, 2025AnnouncementDBV Technologies S.A. issued a press entitled “DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
DBV Technologies financials
Famous investors that hold DBVT
3 of the 50 well-known investors we track reported holding DBVT in their latest 13F filing. The largest position is Israel Englander's, worth $6.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 552,991 | $6.5M | 0.0% | +107% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 276,134 | $3.2M | 0.0% | +1112% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 173,028 | $2M | 0.0% | -55% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DBVT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | MPM BioImpact LLC | 13G/A | 4.8% |
| Nov 13, 2026 | MPM BioImpact LLC | 13G/A | 4.8% |
| Nov 12, 2026 | Invus Public Equities, L.P. | 13G/A | 7.3% |
| Nov 12, 2026 | Invus Public Equities, L.P. | 13G/A | 7.3% |
Questions about DBV Technologies S.A. (DBVT) stock
Who owns the most DBVT stock?
The largest reported owner of DBV Technologies S.A. (DBVT) is Mpm Bioimpact LLC, with 1.2% of the company. In total, 77 funds and institutions reported holding DBVT at the end of Q2 2026, together about 7% of the shares. See the largest owners.
Are DBVT insiders buying or selling?
In the last 12 months, DBVT insiders reported no open-market purchases and 7 sales worth $15.5M. The latest trade was on Jul 29, 2026. See every trade.
What is the short interest in DBVT?
As of Oct 30, 2026, 806,674 DBVT shares were sold short, 0.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 483,590 shares, buying them all back would take about 1.7 trading days (days to cover). See the history.
Which famous investors hold DBVT?
3 of the 50 well-known investors we track reported DBVT in their latest 13F filing, including Israel Englander, Ken Griffin, Stanley Druckenmiller. The largest position is worth $6.5M. See all holders.
Executive pay
DBV Technologies's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025, up 107% from $1.6M the year before. In the last 12 months, DBV Technologies's executives and directors bought no stock on the open market and sold $15.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.